Browse News

Found 88 articles

• 

  Clinical Catch-Up: December 7-11

  12/14/2020

  It was an unusually busy week for clinical trial updates, largely because of the annual ASH meeting from Sunday December 5 through Wednesday December 9. There were also other meetings and the usual corporate updates.

• HOOKIPA Pharma Announces Closing of Public Offering of $80.9 Million of Common Stock and Preferred Stock, Including Full Exercise of Underwriters’ Option

  12/11/2020

  HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the closing of its previously announced underwritten public offering of an aggregate of 3,910,000 shares of its common stock and 2,978 shares of its Series A convertible preferred stock (the “Offering”). The public offering price of each share of common stock is $11.75 and the pub

• HOOKIPA Pharma Announces Pricing of Public Offering of Common Stock and Preferred Stock

  12/9/2020

  HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the pricing of an underwritten public offering of 3,400,000 shares of its common stock and 2,978 shares of its Series A convertible preferred stock (the “Offering”).

• HOOKIPA Pharma Announces Proposed Public Offering of Common Stock and Preferred Stock

  12/8/2020

  HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it intends to offer and sell shares of its common stock and shares of Series A convertible preferred stock in an underwritten public offering (the “Offering”)

• 

  Clinical Catch-Up: November 30-December 4

  12/7/2020

  It was a moderately busy week for clinical trial news, with some important reports coming out about COVID-19 vaccines. Here’s a look.

• HOOKIPA Interim Phase 1 Monotherapy Data of HB-201 for the Treatment of Advanced HPV16+ Cancers Shows Promising Anti-Tumor Activity and Favorable Tolerability

  12/7/2020

  Data demonstrate responses and stable disease in some head and neck cancer patients who all received at least two prior therapies and progressed on a PD1 inhibitor

• Amicus Therapeutics Appoints Michael A. Kelly to its Board of Directors

  12/2/2020

  Amicus Therapeutics (Nasdaq: FOLD) today announced the election and appointment of Michael A. Kelly to its Board of Directors. Mr. Kelly is a proven leader with more than two decades of executive experience in the life sciences industry serving in various strategic finance and operations positions, including Chief Financial Officer and board member of multiple biotechnology companies. John F. Crowley, Chairman and Chief Executive Officer of A

• HOOKIPA Announces Positive Phase 2 Interim Safety, Immunogenicity, and Efficacy Data for its Cytomegalovirus Vaccine Candidate HB-101

  11/30/2020

  Early interim data show Cytomegalovirus (CMV)-negative kidney transplant recipients vaccinated with three doses of HB-101 had reduced incidence of CMV viremia, reduced antiviral use and no CMV disease

• HOOKIPA Pharma Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

  11/12/2020

  HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reports its financial results for the third quarter ended September 30, 2020 and provides a corporate update. “The third quarter saw continued advancement and validation of our clinical development programs, with a focus on our oncology pipeline of replicating arenavirus-based

• HOOKIPA Pharma to Participate in Upcoming Investor Conferences in November

  11/11/2020

  HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate in two upcoming virtual investor conferences: The SVB Leerink Oncology 1x1 Day, November 19, 2020 The Piper Sandler 32 nd Annual Virtual Healthcare Conference, November 30 – December 3, 2020 HOOKIPA will participate

• HOOKIPA Pharma To Report Third Quarter 2020 Financial Results on November 12, 2020

  11/3/2020

  HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release financial results for the third quarter ended September 30, 2020 before the market opens on Thursday, November 12, 2020.

• 

  Clinical Catch-Up: October 26-30

  11/2/2020

  It was a particularly busy week for announcements about clinical trials, both related to COVID-19 and everything else. Here’s a look.

• HOOKIPA Announces First Patient Dosed in Phase 1/2 Clinical Trial for HB-202/HB-201 Alternating Vector Therapy to Treat Human Papillomavirus 16-Positive Cancers

  10/29/2020

  - HB-202/HB-201 alternating two-vector therapy is added as an additional arm that expands the ongoing HB-201 clinical trial  - Pre-clinical data show that adding an additional arenaviral vector to achieve alternating two-vector therapy enhances immune response

• 

  BioSpace Movers & Shakers, Oct. 23

  10/23/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• HOOKIPA Appoints Prof. Jean-Charles Soria, Director General of the Gustave Roussy Cancer Center in Paris, to its Board of Directors

  10/19/2020

  HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, announced the appointment of Professor Jean-Charles Soria, M.D., Ph.D., to its Board of Directors.

• HOOKIPA Pharma to Present at SVB Leerink’s CybeRx Series Vaccine Forum

  9/16/2020

  HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, announced that HOOKIPA’s management team will participate and present at SVB Leerink’s CybeRx Series: Vaccine Forum, taking place September 23 – 24, 2020:

• HOOKIPA Pharma’s LCMV-based Immunotherapy for HPV16+ Cancers Demonstrates High Immunogenicity, According to Peer Reviewed Article

  9/16/2020

  HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced a publication in the peer reviewed, open access journal OncoImmunology of a paper on HB-201,

• HOOKIPA Pharma to Present at Upcoming Conferences in September

  9/9/2020

  HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate in the following virtual investor conferences in September: H.C. Wainwright 22 nd Annual Global Investment Conference, September 14-16, 2020 Presentation: Monday, September

• HOOKIPA Pharma Reports Second Quarter 2020 Financial Results and Provides a Corporate Update

  8/13/2020

  HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, reports its financial results for the second quarter ended June 30, 2020 and provides a corporate update.

• HOOKIPA Pharma To Report Second Quarter 2020 Financial Results on August 13, 2020

  8/4/2020

  HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, announced that it will release financial results for the second quarter ended June 30, 2020 before the market opens on Thursday, August 13, 2020.